Erratum: Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation (Diabetes Care (2017) 40 (1668-1677) DOI: 10.2337/dc17-1116);Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation

Diabetes Care

Volumn 40, Issue 12, 2017, Pages 1668-1677

  Herman, William H ^a   Pan, Qing ^b   Edelstein, Sharon L ^b   Mather, Kieren J ^c   Perreault, Leigh ^d   Barrett Connor, Elizabeth ^e   Dabelea, Dana M ^d   Horton, Edward ^f   Kahn, Steven E ^g   Knowler, William C ^h   Lorenzo, Carlos ⁱ   Pi Sunyer, Xavier ^j   Venditti, Elizabeth ^k   Ye, Wen ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f JOSLIN DIABETES CENTER   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j NewYork Presbyterian Hospital   (United States)

^k UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; METFORMIN; PLACEBO; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; PRESCRIPTION; REGULATORY MECHANISM; REMISSION; RISK ASSESSMENT; RISK REDUCTION; BODY MASS; COMPLICATION; DISEASE EXACERBATION; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; LIFESTYLE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; EXERCISE; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; METFORMIN; MIDDLE AGED; OBESITY; OVERWEIGHT; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME;

EID: 85036625950     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-er04     Document Type: Erratum

References (16)

1. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
2. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ 2011;343: d7163 DOI: 10.1136/bmj.d7163
3. Sussman JB, Kent DM, Nelson JP, Hayward RA. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ 2015;350: h454
4. Hofer TP, Sussman JB, Hayward RA. New studies do not challenge the American College of Cardiology/American Heart Association lipid guidelines. Ann Intern Med 2016;164:683-684
5. Smith SC Jr, Haslam D. Abdominal obesity, waist circumference and cardio-metabolic risk: awareness among primary care physicians, the general population and patients at risk-the Shape of the Nations survey. Curr Med Res Opin 2007; 23:29-47
6. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes [published correction appears in Diabetes Care 1999;22:1389]. Diabetes Care 1999;22:623-634
7. Rubin RR, Fujimoto WY, Marrero DG, et al.; DPP Research Group. The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials 2002;23:157-171
8. Friedman JH, Meulman JJ. Multiple additive regression treeswith application in epidemiology. Stat Med 2003;22:1365-1381
9. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, Springer, 2001
10. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005; 61:92-105
11. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA. Regressionmodelling strategies for improved prognostic prediction. Stat Med 1984;3: 143-152
12. D'Agostino RB, Nam BH. Evaluation of the performance of survival analysis models: Discrimination and Calibrationmeasures. In: Handbook of Statistics, Survival Methods. Vol 23. Balakrishnan N, Rao CR, Eds. Amsterdam, Elsevier BV, 2004, p 1-25
13. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006;26:565-574
14. Yudkin JS, Montori VM. The epidemic of prediabetes: themedicine and the politics. BMJ 2014; 349:g4485 DOI: 10.1136/bmj.g4485
15. Davidoff F. Can knowledge about heterogeneity in treatment effects help us choose wisely? Ann Intern Med 2017;166:141-142
16. Ely EK, Gruss SM, Luman ET, et al. A national effort to prevent type 2 diabetes: participant-level evaluation of CDC's National Diabetes Prevention Program. Diabetes Care 2017;40:1331-1341